A vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor (TKI) used for the treatment of advanced kidney cancer. Votrient works by blocking the development of a new blood supply (angiogenesis) to the tumour, thereby starving the tumour of nutrients and oxygen needed to grow, and interfering with the growth of cancer cells. Votrient is a type of angiogenesis inhibitor. Pazopanib is the chemical (or generic) name of the drug, while Votrient is the brand (or trade) name under which the drug is licensed and sold.

Share this Post!